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Abstract
Background: Gastric adenocarcinoma is rare in children and adolescents, with about 17 cases under age 21 in the
world’s literature. We report a case of invasive well-differentiated metastatic gastric cancer in a Brazilian 12-year-old
boy without documented familial history of cancer.
Case presentation: The patient, diagnosed with metastatic disease, died seven months after surgery. DNA from
intra-surgical specimens revealed a TP53 mutation at codon 337 (p.R337H) in samples with neoplastic cells
(dysplasia, tumor and metastasis) but not in non-transformed cells (incomplete intestinal metaplasia and non-
involved celiac lymph node). In all mutation-positive tissues, p.R337H occurred on the same background, a founder
allele identified by a specific haplotype previously described in Brazilian Li-Fraumeni syndrome patients. The same
mutant haplotype, corresponding to a founder mutation present in 0.3% of the general population in Southern
Brazil, was found in the genome of the father. Presence of this inherited haplotype in the tumor as well as in the
father’s germline, suggests a rare case of microchimerism in this patient, who may have harbored a small number
of mutant cells originating in another individual, perhaps a dizygotic twin that died early in gestation.
Conclusion: This case represents one of the earliest ages at diagnosis of gastric cancer ever reported. It shows that
cancer inheritance can occur in the absence of an obvious germline mutation, calling for caution in assessing early
cancers in populations with common founder mutations such as p.R337H in Southern Brazil.
Background
Gastric cancer is the 4
th most common cancer in both
genders in Brazil, as observed in population-based can-
cer registries across the country, with incidence rates
varying from 22.4 to 53.6 per 100.000 individuals in the
States of Goiania and São Paulo, respectively [1]. Despite
recent reduction in incidence and mortality observed in
the country, occurrence of gastric cancer remains
amongst the highest worldwide, in contrast with the
sharp decline observed in many countries over recent
years [2,3]. The reasons for high incidence are still
unclear and are likely to involve multiple etiological
factors.
In recent studies on cancer occurrence in Li-Frau-
meni syndrome subjects who are carriers of germline
TP53 mutations in Brazil, gastric cancer appears to be
relatively common, representing the 4
th most common
type of cancer [4]. Germline TP53 mutations are the
underlying genetic defect of Li Fraumeni Syndrome
(LFS) and Li-Fraumeni-like Syndrome (LFL), a set of
familial syndromes of predisposition to multiple, early
cancer, characterized by an excess risk of adrenocorti-
cal carcinoma in early childhood, soft tissue sarcoma,
bone sarcoma and brain tumors in adolescence, breast
cancer in young adult women and multiple other can-
cers later in life [5]. An excess risk of colorectal cancer
in young adults has been reported as well as earlier
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the general population [6,7].
In Southern Brazil, occurrence of LFS/LF appears to
be frequently associated with a TP53 mutation at codon
337 (c.1010G > A, Arg337His). The mutation is borne
by a specific TP53 haplotype characterized by the allele
T of SNP rs9894946, located in the 3’ non-coding region
of the TP53 gene. Data from two states in Brazil (Parana
and Rio Grande do Sul) indicate that this mutant haplo-
type is present in about 0.3% of the general population,
which is much higher than the estimated frequency of
other TP53 germline mutations [8]. This mutation,
which affects a residue of the oligomerization domain of
the p53 protein, has particular functional and regulatory
properties that differ from most common LFS TP53
mutations. Structural studies have shown that the muta-
tion affects the capacity of p53 to form oligomers with
high DNA-binding capacity in a pH dependent manner
[9]. This dependence upon pH may explain the incom-
p l e t ep e n e t r a n c ea n dt h ew i d ep h e n o t y p i cv a r i a t i o n s
observed in many families carrying the p.R337H
mutation.
In this report, we describe a case of gastric cancer in a
12 year-old-boy with no documented familial history of
cancer. Given the high frequency of the p.R337H muta-
tion in the Brazilian population, we have analyzed surgi-
cal biopsies of this patient for the presence of this
particular mutation. The mutation was found in biopsies
containing tumor, but not in those with non-neoplastic
tissues. The father was also found to carry the same
germline p.R337H TP53 mutation. This observation
highlights one of earliest cases of gastric cancer ever
described and identifies the TP53 mutant p.R337H as a
possible underlying genetic cause.
Case Presentation
A 12-year-old boy with no documented familial history
of cancer presented weakness, malaise, abdominal pain,
dysphagia and loss of 14 kg before referral. Upper diges-
tive endoscopy detected a 3.5 cm-ulcerated lesion in the
cardia. Surgical exploration revealed an inoperable gas-
tric tumor with adjacent lymph-node involvement, his-
topathologically proven liver metastases and probable
diaphragm, esophageal and celiac axis infiltration. A gas-
trostomy was performed and the patient received che-
motherapy without significant response. The patient
died with disseminated disease after seven months.
Methods
The patient was referred to the Department of Abdom-
inal Surgery of Hospital AC Camargo, São Paulo, Brazil,
and biopsies were obtained during diagnostic endoscopy
and surgery. The biopsied samples included tissues fixed
in 10% buffered formalin and embedded in paraffin
(FFPE, Formalin-Fixed, Paraffin-Embedded) and a frozen
liver metastasis sample. DNA was extracted from areas
of gastric tissue sections defined by a pathologist as nor-
mal, metaplastic, dysplatic or cancerous. Blood from
relatives was obtained after genetic counseling and
informed consent. DNA was extracted from FFPE tis-
sues and white blood cells using standard protocols.
TP53 mutations were detected by direct sequencing of
the entire coding region of the gene using an automated
procedure and protocols as described elsewhere [10].
Immunohistochemistry was performed using the follow-
ing antibodies for p53 (DO-7, DakoCytomation,
Glostrup, Denmark), E-cadherin (36, BD Transduction,
San Jose, CA), MLH1 (G168-728, BD Biosciences Phar-
migen, San Jose, CA), MSH2 (G219-1129, BD Bios-
ciences Pharmigen, San Jose, CA), PMS2 (A16-4, BD
Biosciences Pharmigen, San Jose, CA) and MSH6 (44/
M S H 6 ,B DB i o s c i e n c e sP h a r m i g e n ,S a nJ o s e ,C A )
expression.
Genetic and Molecular Pathology findings
Endoscopic biopsies included intestinal metaplasia in the
cardia region (S1) and high-grade dysplasia/in situ gas-
tric carcinoma (S2). Surgical biopsies included liver
metastasis (S3M), well-differentiated gastric adenocarci-
noma (S3G) and a histopathologically normal celiac
lymph node (S4L). TNM classification was T4N2M1.
Despite early-onset, tumor histology did not support a
case of Hereditary Diffuse Gastric Cancer (HDGC).
Immunohistochemistry showed E-cadherin membrane
expression in tumor cells. No alterations were found in
MLH1, MSH2, PMS2 and MSH6 expression, ruling
against an extra-colonic manifestation of Lynch Syn-
drome (data not shown). Figure 1 shows immunostain-
ing for p53 in metaplasia (Figure 1A) and in gastric
adenocarcinoma (Figure 1B). In the latter, all cancer
cells showed strong positivity in the nucleus as well as
weak cytoplasmic staining. In metaplasia, p53 was
detected in the nucleus of cells in small, defined areas
with intestinal differentiation (as shown by the presence
of goblet cells) whereas areas of non-intestinal metapla-
sia were negative for p53 expression. Sequencing of
TP53 exons 2 to 11 identified wild-type sequence (CGC)
in S1 (metaplasia) while S2, S3G and S3M showed a
mutation at codon 337 (c.1010G > A, p.R337H) (Figure
2A). The celiac lymph node (S4L) was negative for p.
R337H (data not shown).
Presence of the founder haplotype associated with p.
R337H was assessed by analysis of SNP 28 (rs9894946)
in the TP53 gene with the T allele indicating the foun-
der haplotype [11]. This allele was detected in the
patient’s samples containing p.R337H (S2, S3G and
S3M) but not in those with wild-type sequence (Figure
2B). Allele-specific PCR demonstrated that p.R337H was
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the founder haplotype (data not shown). Presence of p.
R337H was confirmed by Restriction Length Fragment
Polymorphism (RFLP) using HhaI, which cuts within
c o d o n3 3 7 ,i nS 2 ,S 3 Ga n dS 3 Mb u tn o ti nS 1o rS 4 L
(data not shown). Genomic DNA was obtained from
peripheral blood of the father, mother and of one
brother. The mutant haplotype was constitutive (in het-
erozygosity) in the father’s genomic DNA (Figure 2),
whereas mother and brother were wild-type for TP53.
DNA from peripheral blood cells of the patient was not
available.
Discussion
This case is one of the earliest cases of gastric cancer
ever reported. Gastric adenocarcinoma is extremely
uncommon under 21 years of age [12]. Data from Brazi-
lian cancer registries do not show any evidence of
occurrence of gastric adenocarcinoma in children or
teenagers [13]. This patient was the youngest case of
gastric cancer over a period of 18 years in the pathology
archives of Hospital AC Camargo, one of the largest
cancer centers in Brazil. The patient did not present any
evidence of familial history of cancer and had no report
of personal history of other disease including cancer. In
previous studies, we observed that the TP53 p.R337H
mutation is present in the germline of about 1:300 indi-
viduals (0.3%) in Southern Brazil as the consequence of
a founder effect predisposing to early cancer [8]. How-
ever, the penetrance of this mutation is incomplete. In
families with clinical definitions of LFS/LFL, about 25 to
30% of p.R337H carriers remain apparently cancer-free
over their lifetime (compared to a penetrance of over
90% in carriers of germline TP53 mutations occurring at
“hotspot” codons). Furthermore, the penetrance at age
30 is about 15%, compared to 50% in carriers of muta-
tions at “hotspot” codons. Because of this incomplete
penetrance, a germline p.R337H mutation may be pre-
sent in individuals without specific familial cancer his-
tory, in particular in the absence of extensive pedigree
data. These considerations led us to test for the pre-
sence of p.R337H in retrospective, pathology archived
tissues of this very young case.
The TP53 mutation p.R337H, borne by a haplotype
carrying the T allele of rs9894946 (SNP28) was detected
in tumor and metastasis but not in non-cancer tissues
of this 12-year-old patient. This haplotype corresponds
to the documented founder allele detected in many Bra-
zilian LFS/LFL families and is present in only 2% of Bra-
zilians. On the other hand, p.R337H has never been
documented as a somatic mutation in any cancer at the
IARC TP53 database (http://www-p53.iarc.fr). Therefore,
the probability that the mutation may arise as somatic
mutation on the allele carrying SNP28 independently of
the founder mutation is extremely low. Moreover,
neither the p.R337H mutation nor the T allele of
rs9804946 was detected in non-tumor tissues of the
patient, although both variants were detected in cancer
tissues. The presence of the founder haplotype in
tumor, but not in non-tumor tissue of the patient is
therefore highly puzzling. The analysis was repeated
multiple times by different technicians and using differ-
ent DNA extracts, ruling out a technical artifact. On the
other hand, the hypothesis of a selective loss of hetero-
zygosity for p.R337H both in metaplasia and in the non-
involved celiac lymph node seems extremely unlikely.
Consistent with a germline origin, the mutant haplotype
was found in the father’sD N A ,b u tn o ti nt h em o t h e r
and a brother. This observation indicates that the
mutant haplotype detected in the patient’s tumor is of
paternal origin.
The mechanisms that have led to the presence of this
mutant haplotype only in cancer cells of the patients are
obscure. The results are consistent with the hypothesis
Figure 1 Immunodetection of p53 in endoscopic (A) or surgical
(B) biopsies. A) endoscopic biopsy in the cardia region, showing
areas of metaplasia including areas with intestinal type. Sections
were immunostained with anti-p53 DO7 (Dako) using standard
protocols. Stromal tissue was negative. Bar: 10 μm;
da Silva et al. BMC Cancer 2011, 11:449
http://www.biomedcentral.com/1471-2407/11/449
Page 3 of 5that the patient may have harbored two populations of
cells, one containing the paternal TP53 wild-type allele,
and another one containing the paternal TP53 mutant
allele, the latter present at very low levels, undetectable
by sequencing in most tissues. The maternal, wild-type
allele appears to be identical in both cell populations.
This situation would be consistent with genetic micro-
chimerism. Microchimerism refers to harboring a small
number of cells or DNA from a genetically different
individual, often due to maternal-fetal or feto-fetal traf-
ficking during pregnancy [14-16]. In this patient, we
suggest that microchimerism may have been caused by
Figure 2 Sequence at codon 337 of TP53 and at SNP 28 (rs9894946) in DNA extracted from patient’s biopsies (S1, S2, S3G and S3M)
and from the father’s peripheral blood cells. Direct sequencing was performed as described in (http://www-p53.iarc.fr/Download/
TP53_DirectSequencing_IARC.pdf) A) As indicated by arrows, metaplasia (S1) showed the wild-type sequence of codon 337 (G allele in
homozygosis). The dysplastic (S2), the neoplastic (S3G) and the metastastic (S3M) tissues were heterozygous at codon 337, with a G to A
transition corresponding to the p.R337H mutation. B) Sequencing for SNP28 showed the wild-type sequence (CCG) in S1 and the presence of T
allele in S2, S3G and S3M. The mutant haplotype was detected in father’s germline.
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one of whom had the paternal mutant haplotype and
underwent very early developmental failure. It should be
noted that the loss of a dizygotic fetus has not been
documented in the mother’s history of pregnancy, mak-
ing this hypothesis unverifiable.
Conclusions
This is, to our knowledge, the first report suggesting
microchimerism for germline mutation that has led to
cancer development. In contexts other than Southern
Brazil, where the unique p.R337H founder haplotype is
frequent and well characterized, such an event would
have been undetected and interpreted as a somatic
mutation. Our results therefore call for caution when
assessing the genetic status of early or uncommon can-
cers in populations with common founder haplotypes.
Testing tumor DNA in addition to genomic DNA
should be considered in such patients to rule out the
possibility of microchimerism.
Consent
Written informed consent could not be obtained from
the patient for publication of this case report and any
accompanying images because the patient has died. The
patient’s mother has consented to publishing the data.
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